Patients received bevacizumab 15 mg/kg intravenously (IV) on cycle 1 day 1 and carboplatin IV AUC = 5 on cycle 1 day 8. Patients with HER2-positive disease also received trastuzumab.
GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...
Median OS increased from 11 to 13 months in IMNN-001 treatment group based on latest data analysis No change in IMNN-001 favorable safety profile including no reports of serious immune-related adverse ...
9d
Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001Vertical integration of major ...
The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell lung cancer.
LONDON, UK I, 2024 I GSK plc (LSE/NYSE: GSK) today announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula ...
This phase 3 trial (NCT03884101) enrolled 842 patients with stage III-IV or recurrent endometrial ... or paclitaxel at 175 mg/m 2 plus carboplatin (area under the curve, 6 mg/mL per min) once ...
or placebo administered concurrently with both sequential regimens of paclitaxel (80 mg/m 2 IV weekly) for 12 weeks plus carboplatin (AUC of 5 IV for 4 doses) followed by investigator’s choice of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback